XML 61 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2

Investment in LipoMedix Pharmaceuticals Ltd. (Details) - USD ($)				1 Months Ended	12 Months Ended
	Nov. 15, 2021	Nov. 11, 2021	Sep. 01, 2021	Mar. 31, 2021	Jul. 31, 2022	Nov. 30, 2021
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Issued and outstanding ordinary shares, percentage					84.00%
Interest rate increase			15.00%
Ordinary shares (in Shares)	15,975,000
Purchase price	$ 0.1878
Aggregate purchase price	$ 3,000,000
Noncontrolling interest					$ 8,000
Warrant [Member]
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Ordinary shares (in Shares)		15,975,000
Purchase price		$ 0.1878
Maximum [Member]
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Percentage of noncontrolling interest					84.00%
Minimum [Member]
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Percentage of noncontrolling interest					16.00%
Lipomedix Pharmaceuticals Ltd. [Member]
Investment in LipoMedix Pharmaceuticals Ltd. (Details) [Line Items]
Maturity date				In March 2021, the Company provided bridge financing in the principal amount of up to $400,000 to LipoMedix with a maturity date of September 1, 2021, and an interest rate of 8% per annum.
Principal amount				$ 400,000
Interest rate				8.00%
Ordinary shares (in Shares)					15,975,000
Aggregate purchase price					$ 3,000,000
Principal amount outstanding						$ 400,000
Accrued interest						$ 21,800
Cash payment					$ 2,600,000

X

- Definition

Accrued interest.

+ References

No definition available.

+ Details

Name:	rfl_AccruedInterest
Namespace Prefix:	rfl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of aggregate purchase price.

+ References

No definition available.

+ Details

Name:	rfl_AmountOfAggregatePurchasePrice
Namespace Prefix:	rfl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Cash payment.

+ References

No definition available.

+ Details

Name:	rfl_CashPayment
Namespace Prefix:	rfl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	rfl_InvestmentinLipoMedixPharmaceuticalsLtdDetailsLineItems
Namespace Prefix:	rfl_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	rfl_IssuedAndOutstandingOrdinarySharesPercentage
Namespace Prefix:	rfl_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Noncontrolling interest percentage.

+ References

No definition available.

+ Details

Name:	rfl_NoncontrollingInterestPercentage
Namespace Prefix:	rfl_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	rfl_PurchasePrice
Namespace Prefix:	rfl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The average effective interest rate during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1F
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateDuringPeriod
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Incremental percentage increase (decrease) in the stated rate on a debt instrument.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentInterestRateIncreaseDecrease
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentMaturityDateDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of the required periodic payments applied to principal.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentPeriodicPaymentPrincipal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719

+ Details

Name:	us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of noncontrolling interests which are redeemable by the parent entity, classified as other equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph (12)(c)
-URI https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph 15
-URI https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph (16)(c)
-URI https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 3A
-Subparagraph 14
-URI https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764

+ Details

Name:	us-gaap_RedeemableNoncontrollingInterestEquityOtherCarryingAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

+ Details

Name:	us-gaap_SharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_OwnershipAxis=rfl_LipomedixPharmaceuticalsLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: